Meta Scales Back Ambitions for AR Glasses
An anonymous reader shares a report: In March 2020, as the Covid-19 pandemic began to transform the world, the company then known as Facebook struck a deal to buy all the augmented reality displays made by British firm Plessey. At the time, the deal appeared to be a savvy way of squeezing out Apple in the competition to develop AR glasses, as Plessey was one of the few makers of AR displays. Three years on, however, the deal has turned into a bust for Meta. Development of Plessey's technology has stalled, say people with direct knowledge of the effort. Facebook, now called Meta Platforms, has struggled to make Plessey's displays bright enough for use in its AR glasses under development and to reduce defects that crop up in the manufacturing process. Earlier this year, Meta decided to abandon Plessey's microLED tech in favor of an older display technology, liquid crystal on silicon or LCoS. The decision is one of several Meta has made, for either technological or cost-saving reasons, that will reduce the edge that the AR glasses have over existing AR headsets like Microsoft's HoloLens. The episode highlights the twists and turns Meta is navigating as it tries to stay ahead of Apple and other rivals in the still-developing market for AR and virtual reality. Meta was early to the VR market with its Quest headsets and has been working on developing AR glasses to get ahead of rivals like Snap which are trying to develop similar products. Now it faces competition from Apple, which last month unveiled its mixed-reality headset, the Vision Pro, which will be available early next year. At the same time, Meta is under pressure from investors to curb the more than $10 billion it is spending annually at the Reality Labs division developing its AR and VR products. Technical setbacks have forced Meta to delay the timeline for releasing AR glasses multiple times, and it isn't anticipating releasing a pair of AR glasses to the public until at least 2027.
Read more of this story at Slashdot.